Drug Approval | May 29, 2025
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
EBITDA for the period rose by 23.2% to Rs. 3,797 million
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
The inspection concluded with 6 observations and none of them were related to Data Integrity
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
